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This report reviews a case of dermatomyositis presenting with weakness and extensive calcification in
an adult. While dermatomyositis is not uncommon in adults, it is uncommon for calcifications to be
present. Children develop calcifications more frequently than adults. When present in adults, small
calcifications on areas of frequent trauma such as elbows and fingers are more common. However, this
patient presented with large calcified deposits in his abdomen and extremities. His treatment and
course are described. [West J Emerg Med. 2012;13(1):136–138.]
CASE REPORT
A 26-year-old Hispanic male presented to the emergency
department with progressive weakness during the previous
year. This weakness initially started in his lower extremities,
when he noticed difﬁculty when ascending stairs; however, it
progressed to involve his upper extremities in the following
months. He also had complaints of joint pain, generalized
fatigue, ‘‘bumps,’’ and ‘‘hard places’’ over his abdomen and
thighs, as well as a rash that was more pronounced on his face,
arms, and legs. Of note, he had been admitted to another
hospital several months before and treated with aggressive
hydration for rhabdomyolysis. He improved slightly after that
admission, but the weakness subsequently progressed to the
point that he was unable to ambulate on his own power. He was
given a prescription for an unknown medication on discharge
from his previous hospitalization but it was never ﬁlled. His
past surgical history was signiﬁcant for an appendectomy about
1 year prior; his family history was unremarkable.
On physical examination, the patient had normal vital
signs. He was noted to have a diffuse hyperpigmented rash over
his face, more prominent on his cheeks and other sun-exposed
portions of his body. He was also noted to have taut skin and a
ﬁrm, nonmobile, tender mass in his right lateral abdominal and
ﬂank area that began at the costal margin and continued into his
right pelvis. This ﬁrm area extended from the posterior axillary
line to almost the midline of his abdomen. He had other similar
but smaller masses in his left upper and lower quadrants as well
as on both thighs. On examination, the patient was unable to
raise his arms above his head without assistance. His
neurologic examination showed intact sensation and reﬂexes
throughout with marked weakness in his extremities and trunk.
He demonstrated 2–3/5 strength in both legs proximally with 4/
5 strength in his upper extremities. He had difﬁculty sitting up
without assistance.
His laboratory tests in the emergency department included
a basic metabolic panel that was within normal limits, with
normal calcium levels. The creatine kinase (CK) level,
however, was elevated to 3,501 IU/L, while serum aldolase was
29.7 U/L (reference, 1.5–8.1 U/L) and lactate dehydrogenase
(LDH) was 728 IU/L (reference, 100–240 IU/L). He had a mild
transaminitis with an aspartate aminotransferase level of 207
IU/L and an alanine aminotransferase level of 148 IU/L. A
computed tomography of the abdomen and pelvis was
completed. The ofﬁcial read commentedon calciﬁcations in the
right rectus abdominis muscle, external oblique, and
subcutaneous fat, as well as calciﬁcations in the left external
oblique muscle and left rectus abdominis. The patient was
admitted for further management.
In the hospital, he was aggressively hydrated and given
high-dose steroids as well as methotrexate (Trexall; Teva
Pharmaceuticals USA, North Wales, Pennsylvania).
Rheumatology service was consulted, and a muscle biopsy
conﬁrmed the diagnosis of dermatomyositis with calcinosis
cutis. The patient was then given azathioprine (Imuran;
Prometheus Laboratories Inc, San Diego, California) and he
showed continual improvement throughout his hospital course.
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intensive physical therapy throughout his hospitalization. At
hospital discharge, the patient had 4/5 strength globally and
was able to sit in a chair unassisted. He continues to work
toward ambulation through outpatient physical therapy.
DISCUSSION
Dermatomyositis is a disease that can present in
individuals of all ages, with peak incidence in adults during the
ﬁfth and sixth decades of life. It has an incidence of 5.5 per
million people. The exact mechanism for dermatomyositis is
not known, but it is postulated to have an autoimmune
component. Some cases are felt to be paraneoplastic. In most
cases, the rash and proximal weakness appear simultaneously.
However, 30% of patients experience the cutaneous symptoms
without weakness (dermatomyositis sine myositis), and 10%
have muscle weakness without cutaneous symptoms. Initial
cutaneous symptoms often include burning and pruritus, which
may be associated with exposure to ultraviolet light or sunlight.
Muscle weakness is characterized predominantly by proximal
hip and shoulder muscle involvement: patients may have
complaints of difﬁculty standing from a sitting position or
raising their arms above their heads. They also have complaints
of pain and tenderness to their muscles.
1
Laboratory tests to support the diagnosis of
dermatomyositis include serum muscle enzyme concentrations
as well as autoantibody tests. Often, CK, LDH, aldolase, and
aminotransferases are elevated from muscle breakdown.
Patients usually have autoantibodies ranging from nonspeciﬁc
antinuclear antibodies to the more speciﬁc anti–155 kDa.
Electromyography (EMG) is characterized by increased
irritability with spontaneous ﬁbrillation and sharp waves.
Often, skin and muscle biopsies show inﬂammatory changes,
segmental necrosis, or other nonspeciﬁc ﬁndings. The
diagnosis is conﬁrmed through clinical history and
examination of proximal muscle weakness with skin ﬁndings
and 2 of 3 laboratory criteria. These include elevated muscle
enzymes, EMG changes, and tissue biopsy, as described
above.
1
Although this patient had the typical ﬁndings of
dermatomyositis, with conﬂuent photosensitive rash over the
malar area of his face and proximal muscle weakness, he also
suffered from extensive calcinosis. While described as a
complication of dermatomyositis in pediatric and adolescent
patients, calcinosis is much less common in adult patients.
Among the few cases seen in adults, calcinosis is often located
in hard deposits around areas that experience frequent trauma
(elbows and ﬁngers).
2 Socioeconomic status may play a role in
the progression of calcinosis, as demonstrated in case reports
3;
this patient is a migrant worker without insurance. He
demonstrated problems with timely follow-up to ensure he was
getting the appropriate medicines after his initial diagnosis of
rhabdomyolysis.
This patient developed extensive calciﬁcations in the
subcutaneous tissue of his right ﬂank (Figure 1) and abdomen
(Figure 2). This area is not typically affected in adults; however,
the trauma from his appendectomy may have initiated an
Figure 1. Coronal view of computed tomography showing extensive
calcification of right flank.
Figure 2. Sagittal view of computed tomography showing right-
sided calcification as well as small calcific foci on left anterior
abdomen.
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precipitated the formation of the calcium deposits in his
abdominal wall with resultant calcinosis.
4
Treatment is largely based on controlling the likely
autoimmune component of the disease. One possible etiology is
complement-mediated inﬂammation at the vascular level;
another is a direct cytotoxic effect of lymphocytes on the
muscle cells. Initial therapy consists of high-dose steroids.
Immunosuppressant and cytotoxic agents are often given early
in the course in order to wean off steroids, thereby limiting the
toxic effect of chronic steroids. Methotrexate, azathioprine, and
mycophenolate mofetil are common agents used in
dermatomyositis. If this combination of drugs is unsuccessful,
intravenous immunoglobulins have shown promise for short-
term treatment.
5
Calcinosis is a difﬁcult complication to treat. Some studies
have shown success with diltiazem, aluminum hydroxide, and
even alendronate in children.
6,7 However, refractory cases of
calcinosis that cause pain or interferewith function may need to
be referred for surgical excision.
8
Treatments for the rash are ﬁrst focused on controlling
systemic processes, but providing protection is also extremely
important through limiting sun exposure and using sun
protective clothing and sunscreen.
Current theories indicate calcinosis may be a consequence
of untreated or unaggressively treated dermatomyositis. In
juvenile dermatomyositis, early aggressive intervention offers
the best protection from development of calcinosis. This adult
patient had been experiencing symptoms for about 14 months
before he received aggressive treatment, most likely another
factor in his development of calcinosis.
3 This patient suffered to
the point at which he was no longer able to complete his
activities of daily living. Luckily, he showed rapid signs of
improvement with high-dose steroids and azathioprine. He was
given prednisone and azathioprine also as an outpatient with
continued improvement in his symptoms. Initially, intravenous
immunoglobulin was considered because of the severity and
progressive nature of his symptoms; however, it was never
given owing to his response to other medicines.
The overall prognosis for patients treated with
dermatomyositis is good, with a 5-year survival rate of 95% and
a 10-year survival rate of 84%. Those who die from the
condition often have pulmonary or cardiac manifestations as
well. While most persons with dermatomyositis improve and
respond to therapy, up to 30% experience long-term
consequences.
9 At a 2-month follow-up appointment, the
patient was ambulating without assistance and was able to
complete activities of daily living. He still reports some
difﬁculty in standing from low sitting positions but continues to
improve as his disease process is better controlled. The patient
continues to take immunosuppressants and diltiazem. His
calciﬁcations remain, but his pain and symptoms are
controlled.
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